← Evidence map

ArticleCancers2026

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Elena Gabriela Chiorean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

5 papers cite it

2026

this papercites it

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. | OpenQuestion